期刊
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
卷 68, 期 3, 页码 249-258出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00228-011-1120-6
关键词
Vorapaxar; SCH 530348; PAR-1 antagonist; Pharmacokinetics; Pharmacodynamics; Platelet aggregation; Thrombin receptor antagonist
资金
- Merck, Whitehouse Station, NJ, USA
- Merck
Purpose The aim of our study was to evaluate the pharmacology of vorapaxar (SCH 530348), an oral PAR-1 antagonist, in healthy volunteers. Methods and results In two randomized, placebo-controlled studies, subjects received either single ascending doses of vorapaxar (0.25, 1, 5, 10, 20, or 40 mg; n = 50), multiple ascending doses of vorapaxar (1, 3, or 5 mg/day for 28 days; n = 36), a loading dose (10 or 20 mg) followed by daily maintenance doses (1 mg) for 6 days (n = 12), or placebo. Single 20- and 40-mg doses of vorapaxar completely inhibited thrombin receptor activating peptide (TRAP)-induced platelet aggregation (>80% inhibition) at 1 h and sustained this level of inhibition for >= 72 h. Multiple doses yielded complete inhibition on Day 1 (5 mg/day) and Day 7 (1 and 3 mg/day). Adverse events were generally mild, transient, and unrelated to dose. Conclusion Vorapaxar provided rapid and sustained dose-related inhibition of platelet aggregation without affecting bleeding or clotting times.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据